OncoZenge AB Enters into Collaboration with UCLA for Patient Engagement Study
OncoZenge AB, a pioneering pharmaceutical company focused on developing innovative treatments for oral pain, has announced an exciting collaboration with the University of California, Los Angeles (UCLA). This partnership centers around a patient engagement study that aims to uncover the unmet needs in managing oral mucositis pain, particularly as preparations are made for a potential Investigational New Drug (IND) application for their key product, BupiZenge™.
Purpose of the Collaboration
The collaboration seeks to utilize UCLA's renowned expertise in oncology and radiation therapy. By engaging patients and healthcare providers, the study will collect essential data that will help inform the further clinical development of BupiZenge™. This innovative non-opioid lozenge is designed to provide localized and long-lasting relief from the severe oral pain that many cancer treatment patients experience, addressing a significant gap in current therapeutic options.
Statements from Leadership
CEO of OncoZenge, Stian Kildal, expressed enthusiasm about the partnership. He noted, "We are excited to partner with UCLA, a leader in cancer research and patient care. This collaboration not only strengthens our understanding of patient experiences through this engagement study but also aids us in navigating the complexities of the regulatory landscape for a potential IND filing. This brings us closer to offering BupiZenge™ to patients in the U.S. market."
Insights from Clinical Experts
Robert K. Chin, MD, PhD, a Radiation Oncologist at UCLA Health, shared his insights on the collaboration as well, stating, "Oral mucositis is a debilitating side effect for many cancer patients undergoing treatment. By collaborating with OncoZenge on this patient engagement study, we have the opportunity to amplify patient voices and investigate innovative solutions like BupiZenge™, which could drive clinical advancements in the U.S."
Expanding Global Impact
This collaborative initiative aligns seamlessly with OncoZenge's ongoing Phase III preparations in other global markets, reinforcing the company's commitment to establishing meaningful partnerships that will further the advancement of BupiZenge™. The insights from this study are anticipated to play a pivotal role in shaping potential pathways to market, addressing the urgent needs of patients suffering from oral pain due to cancer therapies.
About OncoZenge AB
OncoZenge AB is a clinical-stage pharmaceutical company dedicated to developing simple yet effective treatments for oral pain conditions, particularly those caused by cancer therapy. The company is committed to providing solutions that significantly improve patients' quality of life, making BupiZenge™ a crucial element of their innovative approach to pain management. By focusing on localized, non-opioid treatments, OncoZenge offers an alternative to systemic opioid therapies, reducing the associated risks that come with them.
Contact Information
For additional information, please feel free to reach out to:
Stian Kildal
CEO
Mobile: +46 76 115 3797
Email: stian.kildal@oncozenge.se
Frequently Asked Questions
What is the main focus of the collaboration between OncoZenge and UCLA?
The collaboration primarily targets gathering insights on managing oral mucositis pain to inform the clinical development of BupiZenge™.
What is BupiZenge™?
BupiZenge™ is an innovative lozenge designed to provide localized and long-lasting relief from severe oral pain associated with cancer treatment.
Who are the key individuals mentioned in the collaboration?
Key individuals include Stian Kildal, CEO of OncoZenge, and Robert K. Chin, MD, PhD, a Radiation Oncologist at UCLA Health.
How does this study benefit cancer patients?
This study amplifies patient voices and explores innovative solutions for managing oral pain, addressing significant gaps in existing care options.
What are the next steps for OncoZenge after this collaboration?
OncoZenge will utilize data from the study to navigate the regulatory landscape and work toward a possible IND filing, bringing BupiZenge™ closer to market availability.
